2019 Mar – 2024 Feb | $11.4M

Assessing safety, efficacy and transmission blocking properties of the new anti-malarial KAF156 combined with a new formulation of lumefantrine in children and adults with uncomplicated Plasmodium sp. malaria in West and Central Africa (WANECAM II) European & Developing Countries Clinical Trials Partnership (EDCTP), University of Sciences, Techniques and Technologies of Bamako (USTTB), Mali | Abdoulaye Djimde | Gabon, Burkina Faso, Mali, Niger

Publications similaires

  • 2021 Jan – 2024 Jan

    Increasing the uptake of IPTp-SP through Seasonal Malaria Chemoprevention channel delivery (INTEGRATION study) R-Evolution Worldwide, University of Sciences, Techniques and Technologies of Bamako (USTTB), Mali, Research Institute of Health Sciences (IRSS), Burkina Faso | Kassoum Kayentao | Burkina Faso, Mali

  • 2018 Jan – 2019 Dec

    Establishment of an optimized in vitro screening platform for evaluation of antimalarial compounds against liver stages including hypnozoites of Plasmodium vivax and P. ovale using field isolated parasites Medicines for Malaria Venture (MMV), University of Sciences, Techniques and Technologies of Bamako (USTTB), Mali | Laurent Dembele | Ethiopia, Mali

  • WANECAM

    WANECAM is the West African Network for Clinical Trials of Antimalarial drugs. This network is being supported by grants from the European & Developing Countries Clinical Trials Partnership (EDCTP). The WANECAM 2 project aims to accelerate the development of the  Ganaplacide/lumefantrine  combination for the treatment of uncomplicated malaria by conducting clinical trials in four countries…

  • 2019 Oct – 2022 Oct | $703k

    Using single-cell RNAseq to investigate human malaria parasite transmission dynamics Medical Research Council (MRC), UK, Wellcome Trust Sanger Institute, UK, University of Sciences, Techniques and Technologies of Bamako (USTTB), Mali | Mara K. N. Lawniczak, Abdoulaye Djimde | Africa, Central, Africa, Eastern, Africa, Southern, Mali, United Kingdom

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *